No-Carrier-Added Lutetium-177 Separation Technology Status

Abstract

Medical isotopes are the substantial basis of the diagnostic and therapeutic nuclear medicine. There are irreplaceable advantages for utilizing the nuclear medical technology to diagnose and treat the malignant tumors, cardiovascular and cerebrovascular diseases, neurodegenerative diseases and other major diseases. Lutetium-177 (177Lu) has excellent nuclear physical and chemical properties. In recent years, 177Lu has been widely used in the research and clinical application of targeted nuclide therapy in the western developed countries, and the radio-labeled compounds have showed the good effects in the diagnosis and treatment of tumors, including neuroendocrine tumors, prostate cancer, metastatic disease in bone and etc. 177Lu has been recognized as one of the most promising and dynamic economical theranostic targeted medical radio-isotopesand the global demand for 177Lu can be expected to grow explosively in the future. In this text, the preparation principle of 177Lu and current research status of 177Lu separation technology domestically or internationally, the future market demand and the application prospect were briefly introduced.

Keywords

• neutron irradiation / carrier-added (ca) 177lu / no-carrier-added 177lu / radiochemical separation / targeted radionuclide therapy